CRBU Caribou Biosciences, Inc.
Distress ·
The Berkeley CRISPR company will discontinue vispa-cel and CB-011, cut staff and hire Wedbush. It had $113.8 million in cash on June 30 and expects $15 million to $19 million in restructuring costs.
Caribou's Nasdaq notice covers a window of about two weeks, from June 3 to June 17, 2025, when its closing bid was $1.00 or more. The 8-K does not say what the price did before or after that window.
Caribou will reduce its workforce by 47 employees, discontinue its lupus trial, a CB-012 trial and preclinical research, and focus on CB-010 and CB-011. It reported a preliminary $212.5 million in cash and securities at March 31, 2025.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $11.2 million | $10.0 million |
| Research and development | $109.4 million | $130.2 million |
| Net income (loss) | -$148.1 million | -$149.1 million |
| Cash from operations | -$111.0 million | -$138.2 million |
| Cash and equivalents | $12.4 million | $16.3 million |
| Short-term investments | $127.0 million | $193.2 million |
Opinion Low conviction
With both programs shut, the cash that reaches holders is what matters. At $0.4922 the market pays about 7% to 17% more than our estimate of that cash, and the board has not said it will return any.
Our latest story on this, dated Jun 23, 2025: "Caribou Biosciences regains compliance with Nasdaq $1.00 bid price rule". The story links the filing or release it is based on. Read the story.
Caribou Biosciences, Inc. trades under the ticker CRBU on NASDAQ.
Caribou Biosciences, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Caribou Biosciences, Inc. is 1619856. Its filings are on SEC EDGAR.
107,207,513 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Caribou Biosciences, Inc. under United States.
Our directory classifies Caribou Biosciences, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Caribou Biosciences, Inc. is US1420381089.
aibio.space lists Caribou Biosciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
$11.2 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Caribou Biosciences, Inc. reported a net loss of $148.1 million for the fiscal year ended Dec 31, 2025, and used $111.0 million of cash in operations, per its annual report to the SEC.
$109.4 million in the fiscal year ended Dec 31, 2025, per its annual report.
$112.3 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on Caribou Biosciences, dated Oct 6, 2026: "Caribou explores strategic alternatives and ends its allogeneic CAR-T programs". The Berkeley CRISPR company will discontinue vispa-cel and CB-011, cut staff and hire Wedbush. It had $113.8 million in cash on June 30 and expects $15 million to $19 million in restructuring costs. Source.
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,5.02,7.01,8.01,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,8.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio